{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T17:16:06Z","timestamp":1780420566117,"version":"3.54.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,2,13]],"date-time":"2018-02-13T00:00:00Z","timestamp":1518480000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Imaging Biol"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s11307-018-1168-0","type":"journal-article","created":{"date-parts":[[2018,2,13]],"date-time":"2018-02-13T13:12:37Z","timestamp":1518527557000},"page":"615-622","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["A Nonhuman Primate PET Study: Measurement of Brain PDE4 Occupancy by Roflumilast Using (R)-[11C]Rolipram"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3034-7721","authenticated-orcid":false,"given":"Akihiro","family":"Takano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tolga","family":"Uz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"Garcia-Segovia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gezim","family":"Lahu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahid","family":"Amini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuji","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhisheng","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christer","family":"Halldin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,13]]},"reference":[{"key":"1168_CR1","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S1054-3589(08)60128-3","volume":"44","author":"MD Houslay","year":"1998","unstructured":"Houslay MD, Sullivan M, Bolger GB (1998) The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions. Adv Pharmacol 44:225\u2013342. \n                    https:\/\/doi.org\/10.1016\/S1054-3589(08)60128-3","journal-title":"Adv Pharmacol"},{"issue":"7","key":"1168_CR2","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1111\/j.1476-5381.1996.tb15598.x","volume":"118","author":"H Tenor","year":"1996","unstructured":"Tenor H, Hatzelmann A, Church MK, Schudt C, Shute JK (1996) Effects of theophylline and rolipram on leukotriene C4 (LTC4) synthesis and chemotaxis of human eosinophils from normal and atopic subjects. Br J Pharmacol 118(7):1727\u20131735. \n                    https:\/\/doi.org\/10.1111\/j.1476-5381.1996.tb15598.x","journal-title":"Br J Pharmacol"},{"key":"1168_CR3","first-page":"147","volume":"4","author":"MA Giembycz","year":"2010","unstructured":"Giembycz MA, Field SK (2010) Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD. Drug Des Devel Ther 4:147\u2013158","journal-title":"Drug Des Devel Ther"},{"issue":"5","key":"1168_CR4","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrd4017","volume":"12","author":"C Harrison","year":"2013","unstructured":"Harrison C (2013) Trial watch: PDE4 inhibitor leads wave of target-specific oral psoriasis drugs. Nat Rev Drug Discov 12(5):335. \n                    https:\/\/doi.org\/10.1038\/nrd4017","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"1168_CR5","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.jaad.2012.10.064","volume":"68","author":"PH Schafer","year":"2013","unstructured":"Schafer PH, Day RM (2013) Novel systemic drugs for psoriasis: mechanism of action for apremilast, a specific inhibitor of PDE4. J Am Acad Dermatol 68(6):1041\u20131042. \n                    https:\/\/doi.org\/10.1016\/j.jaad.2012.10.064","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"1168_CR6","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1517\/13543776.2014.968127","volume":"24","author":"A Martinez","year":"2014","unstructured":"Martinez A, Gil C (2014) cAMP-specific phosphodiesterase inhibitors: promising drugs for inflammatory and neurological diseases. Expert Opin Ther Pat 24(12):1311\u20131321. \n                    https:\/\/doi.org\/10.1517\/13543776.2014.968127","journal-title":"Expert Opin Ther Pat"},{"key":"1168_CR7","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.neulet.2015.09.023","volume":"610","author":"Y Zhong","year":"2016","unstructured":"Zhong Y, Zhu Y, He T, Li W, Yan H, Miao Y (2016) Rolipram-induced improvement of cognitive function correlates with changes in hippocampal CREB phosphorylation, BDNF and Arc protein levels. Neurosci Lett 610:171\u2013176. \n                    https:\/\/doi.org\/10.1016\/j.neulet.2015.09.023","journal-title":"Neurosci Lett"},{"issue":"2","key":"1168_CR8","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1037\/0735-7044.119.2.595","volume":"119","author":"JA Davis","year":"2005","unstructured":"Davis JA, Gould TJ (2005) Rolipram attenuates MK-801-induced deficits in latent inhibition. Behav Neurosci 119(2):595\u2013602. \n                    https:\/\/doi.org\/10.1037\/0735-7044.119.2.595","journal-title":"Behav Neurosci"},{"issue":"3","key":"1168_CR9","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/j.neuropharm.2011.08.008","volume":"62","author":"JS Rodefer","year":"2012","unstructured":"Rodefer JS, Saland SK, Eckrich SJ (2012) Selective phosphodiesterase inhibitors improve performance on the ED\/ID cognitive task in rats. Neuropharmacology 62(3):1182\u20131190. \n                    https:\/\/doi.org\/10.1016\/j.neuropharm.2011.08.008","journal-title":"Neuropharmacology"},{"issue":"3","key":"1168_CR10","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0014-2999(96)00969-7","volume":"321","author":"T Imanishi","year":"1997","unstructured":"Imanishi T, Sawa A, Ichimaru Y, Miyashiro M, Kato S, Yamamoto T, Ueki S (1997) Ameliorating effects of rolipram on experimentally induced impairments of learning and memory in rodents. Eur J Pharmacol 321(3):273\u2013278. \n                    https:\/\/doi.org\/10.1016\/S0014-2999(96)00969-7","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"1168_CR11","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.nbd.2008.02.010","volume":"30","author":"Z DeMarch","year":"2008","unstructured":"DeMarch Z, Giampa C, Patassini S et al (2008) Beneficial effects of rolipram in the R6\/2 mouse model of Huntington\u2019s disease. Neurobiol Dis 30(3):375\u2013387. \n                    https:\/\/doi.org\/10.1016\/j.nbd.2008.02.010","journal-title":"Neurobiol Dis"},{"issue":"20","key":"1168_CR12","doi-asserted-by":"publisher","first-page":"13217","DOI":"10.1073\/pnas.172504199","volume":"99","author":"OV Vitolo","year":"2002","unstructured":"Vitolo OV, Sant\u2019Angelo A, Costanzo V, Battaglia F, Arancio O, Shelanski M (2002) Amyloid beta-peptide inhibition of the PKA\/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. Proc Natl Acad Sci U S A 99(20):13217\u201313221. \n                    https:\/\/doi.org\/10.1073\/pnas.172504199","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"1168_CR13","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s00213-007-0999-1","volume":"196","author":"K Rutten","year":"2008","unstructured":"Rutten K, Basile JL, Prickaerts J, Blokland A, Vivian JA (2008) Selective PDE inhibitors rolipram and sildenafil improve object retrieval performance in adult cynomolgus macaques. Psychopharmacology 196(4):643\u2013648. \n                    https:\/\/doi.org\/10.1007\/s00213-007-0999-1","journal-title":"Psychopharmacology"},{"issue":"12","key":"1168_CR14","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1007\/s00259-002-0950-y","volume":"29","author":"JN DaSilva","year":"2002","unstructured":"DaSilva JN, Lourenco CM, Meyer JH, Hussey D, Potter W, Houle S (2002) Imaging cAMP-specific phosphodiesterase-4 in human brain with R-[11C]rolipram and positron emission tomography. Eur J Nucl Med Mol Imaging 29(12):1680\u20131683. \n                    https:\/\/doi.org\/10.1007\/s00259-002-0950-y","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"1168_CR15","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/syn.20114","volume":"55","author":"CA Parker","year":"2005","unstructured":"Parker CA, Matthews JC, Gunn RN, Martarello L, Cunningham VJ, Dommett D, Knibb ST, Bender D, Jakobsen S, Brown J, Gee AD (2005) Behaviour of [11C]R(-)- and [11C]S(+)-rolipram in vitro and in vivo, and their use as PET radiotracers for the quantificative assay of PDE4. Synapse 55(4):270\u2013279. \n                    https:\/\/doi.org\/10.1002\/syn.20114","journal-title":"Synapse"},{"issue":"4","key":"1168_CR16","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.neuroimage.2005.03.017","volume":"26","author":"M Fujita","year":"2005","unstructured":"Fujita M, Zoghbi SS, Crescenzo MS, Hong J, Musachio JL, Lu JQ, Liow JS, Seneca N, Tipre DN, Cropley VL, Imaizumi M, Gee AD, Seidel J, Green MV, Pike VW, Innis RB (2005) Quantification of brain phosphodiesterase 4 in rat with (R)-[11C]Rolipram-PET. NeuroImage 26(4):1201\u20131210. \n                    https:\/\/doi.org\/10.1016\/j.neuroimage.2005.03.017","journal-title":"NeuroImage"},{"issue":"2","key":"1168_CR17","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/BF02245691","volume":"113","author":"P Karlsson","year":"1993","unstructured":"Karlsson P, Farde L, Halldin C, Swahn CG, Sedvall G, Foged C, Hansen KT, Skrumsager B (1993) PET examination of [11C]NNC 687 and [11C]NNC 756 as new radioligands for the D1-dopamine receptor. Psychopharmacology 113(2):149\u2013156. \n                    https:\/\/doi.org\/10.1007\/BF02245691","journal-title":"Psychopharmacology"},{"issue":"10","key":"1168_CR18","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1007\/s00259-009-1156-3","volume":"36","author":"A Varrone","year":"2009","unstructured":"Varrone A, Sjoholm N, Eriksson L et al (2009) Advancement in PET quantification using 3D-OP-OSEM point spread function reconstruction with the HRRT. Eur J Nucl Med Mol Imaging 36(10):1639\u20131650. \n                    https:\/\/doi.org\/10.1007\/s00259-009-1156-3","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"1168_CR19","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/j.neuroimage.2010.10.064","volume":"54","author":"P Zanotti-Fregonara","year":"2011","unstructured":"Zanotti-Fregonara P, Zoghbi SS, Liow JS, Luong E, Boellaard R, Gladding RL, Pike VW, Innis RB, Fujita M (2011) Kinetic analysis in human brain of [11C](R)-rolipram, a positron emission tomographic radioligand to image phosphodiesterase 4: a retest study and use of an image-derived input function. NeuroImage 54(3):1903\u20131909. \n                    https:\/\/doi.org\/10.1016\/j.neuroimage.2010.10.064","journal-title":"NeuroImage"},{"issue":"2","key":"1168_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0017056","volume":"6","author":"P Zanotti-Fregonara","year":"2011","unstructured":"Zanotti-Fregonara P, Liow JS, Fujita M, Dusch E, Zoghbi SS, Luong E, Boellaard R, Pike VW, Comtat C, Innis RB (2011) Image-derived input function for human brain using high resolution PET imaging with [11C](R)-rolipram and [11C]PBR28. PLoS One 6(2):e17056. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0017056","journal-title":"PLoS One"},{"issue":"1","key":"1168_CR21","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/jcbfm.2009.190","volume":"30","author":"VJ Cunningham","year":"2010","unstructured":"Cunningham VJ, Rabiner EA, Slifstein M, Laruelle M, Gunn RN (2010) Measuring drug occupancy in the absence of a reference region: the Lassen plot re-visited. J Cereb Blood Flow Metab 30(1):46\u201350. \n                    https:\/\/doi.org\/10.1038\/jcbfm.2009.190","journal-title":"J Cereb Blood Flow Metab"},{"issue":"1","key":"1168_CR22","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/jcbfm.1995.17","volume":"15","author":"NA Lassen","year":"1995","unstructured":"Lassen NA, Bartenstein PA, Lammertsma AA, Prevett MC, Turton DR, Luthra SK, Osman S, Bloomfield PM, Jones T, Patsalos PN, O'Connell MT, Duncan JS, Andersen JV (1995) Benzodiazepine receptor quantification in-vivo in humans using [C-11] flumazenil and pet\u2014application of the steady-state principle. J Cereb Blood Flow Metab 15(1):152\u2013165. \n                    https:\/\/doi.org\/10.1038\/jcbfm.1995.17","journal-title":"J Cereb Blood Flow Metab"},{"issue":"1","key":"1168_CR23","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1177\/0091270006294529","volume":"47","author":"TD Bethke","year":"2007","unstructured":"Bethke TD, Bohmer GM, Hermann R et al (2007) Dose-proportional intraindividual single- and repeated-dose pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor. J Clin Pharmacol 47(1):26\u201336. \n                    https:\/\/doi.org\/10.1177\/0091270006294529","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"1168_CR24","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.pupt.2010.03.011","volume":"23","author":"A Hatzelmann","year":"2010","unstructured":"Hatzelmann A, Morcillo EJ, Lungarella G, Adnot S, Sanjar S, Beume R, Schudt C, Tenor H (2010) The preclinical pharmacology of roflumilast\u2014a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther 23(4):235\u2013256. \n                    https:\/\/doi.org\/10.1016\/j.pupt.2010.03.011","journal-title":"Pulm Pharmacol Ther"},{"issue":"1","key":"1168_CR25","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1476-5381.2011.01218.x","volume":"163","author":"KF Rabe","year":"2011","unstructured":"Rabe KF (2011) Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol 163(1):53\u201367. \n                    https:\/\/doi.org\/10.1111\/j.1476-5381.2011.01218.x","journal-title":"Br J Pharmacol"},{"issue":"2","key":"1168_CR26","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1124\/jpet.102.047407","volume":"305","author":"Y Zhao","year":"2003","unstructured":"Zhao Y, Zhang HT, O'Donnell JM (2003) Inhibitor binding to type 4 phosphodiesterase (PDE4) assessed using [3H]piclamilast and [3H]rolipram. J Pharmacol Exp Ther 305(2):565\u2013572. \n                    https:\/\/doi.org\/10.1124\/jpet.102.047407","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"1168_CR27","doi-asserted-by":"publisher","first-page":"749","DOI":"10.2967\/jnumed.108.058305","volume":"50","author":"T Itoh","year":"2009","unstructured":"Itoh T, Abe K, Zoghbi SS, Inoue O, Hong J, Imaizumi M, Pike VW, Innis RB, Fujita M (2009) PET measurement of the in vivo affinity of 11C-(R)-rolipram and the density of its target, phosphodiesterase-4, in the brains of conscious and anesthetized rats. J Nucl Med 50(5):749\u2013756. \n                    https:\/\/doi.org\/10.2967\/jnumed.108.058305","journal-title":"J Nucl Med"},{"issue":"21","key":"1168_CR28","doi-asserted-by":"publisher","first-page":"6546","DOI":"10.1021\/jm900977c","volume":"52","author":"O Bruno","year":"2009","unstructured":"Bruno O, Romussi A, Spallarossa A, Brullo C, Schenone S, Bondavalli F, Vanthuyne N, Roussel C (2009) New selective phosphodiesterase 4D inhibitors differently acting on long, short, and supershort isoforms. J Med Chem 52(21):6546\u20136557. \n                    https:\/\/doi.org\/10.1021\/jm900977c","journal-title":"J Med Chem"},{"issue":"1","key":"1168_CR29","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1177\/1753465812466167","volume":"7","author":"Y Oba","year":"2013","unstructured":"Oba Y, Lone NA (2013) Efficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Ther Adv Respir Dis 7(1):13\u201324. \n                    https:\/\/doi.org\/10.1177\/1753465812466167","journal-title":"Ther Adv Respir Dis"},{"issue":"1-3","key":"1168_CR30","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ejphar.2007.06.045","volume":"573","author":"R Hirose","year":"2007","unstructured":"Hirose R, Manabe H, Nonaka H, Yanagawa K, Akuta K, Sato S, Ohshima E, Ichimura M (2007) Correlation between emetic effect of phosphodiesterase 4 inhibitors and their occupation of the high-affinity rolipram binding site in Suncus murinus brain. Eur J Pharmacol 573(1-3):93\u201399. \n                    https:\/\/doi.org\/10.1016\/j.ejphar.2007.06.045","journal-title":"Eur J Pharmacol"},{"issue":"14","key":"1168_CR31","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1007\/s40265-015-0463-1","volume":"75","author":"KP Garnock-Jones","year":"2015","unstructured":"Garnock-Jones KP (2015) Roflumilast: a review in COPD. Drugs 75(14):1645\u20131656. \n                    https:\/\/doi.org\/10.1007\/s40265-015-0463-1","journal-title":"Drugs"},{"issue":"1","key":"1168_CR32","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1124\/jpet.114.214155","volume":"350","author":"AR Rutter","year":"2014","unstructured":"Rutter AR, Poffe A, Cavallini P, Davis TG, Schneck J, Negri M, Vicentini E, Montanari D, Arban R, Gray FA, Davies CH, Wren PB (2014) GSK356278, a potent, selective, brain-penetrant phosphodiesterase 4 inhibitor that demonstrates anxiolytic and cognition-enhancing effects without inducing side effects in preclinical species. J Pharmacol Exp Ther 350(1):153\u2013163. \n                    https:\/\/doi.org\/10.1124\/jpet.114.214155","journal-title":"J Pharmacol Exp Ther"},{"key":"1168_CR33","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.bbr.2016.01.031","volume":"303","author":"T Vanmierlo","year":"2016","unstructured":"Vanmierlo T, Creemers P, Akkerman S, van Duinen M, Sambeth A, de Vry J, Uz T, Blokland A, Prickaerts J (2016) The PDE4 inhibitor roflumilast improves memory in rodents at non-emetic doses. Behav Brain Res 303:26\u201333. \n                    https:\/\/doi.org\/10.1016\/j.bbr.2016.01.031","journal-title":"Behav Brain Res"},{"issue":"1","key":"1168_CR34","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1523\/JNEUROSCI.5236-10.2011","volume":"31","author":"YF Li","year":"2011","unstructured":"Li YF, Cheng YF, Huang Y, Conti M, Wilson SP, O\u2019Donnell JM, Zhang HT (2011) Phosphodiesterase-4D knock-out and RNA interference-mediated knock-down enhance memory and increase hippocampal neurogenesis via increased cAMP signaling. J Neurosci 31(1):172\u2013183. \n                    https:\/\/doi.org\/10.1523\/JNEUROSCI.5236-10.2011","journal-title":"J Neurosci"},{"issue":"8","key":"1168_CR35","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1111\/j.1476-5381.2011.01524.x","volume":"164","author":"O Bruno","year":"2011","unstructured":"Bruno O, Fedele E, Prickaerts J, Parker LA, Canepa E, Brullo C, Cavallero A, Gardella E, Balbi A, Domenicotti C, Bollen E, Gijselaers HJM, Vanmierlo T, Erb K, Limebeer CL, Argellati F, Marinari UM, Pronzato MA, Ricciarelli R (2011) GEBR-7b, a novel PDE4D selective inhibitor that improves memory in rodents at non-emetic doses. Br J Pharmacol 164(8):2054\u20132063. \n                    https:\/\/doi.org\/10.1111\/j.1476-5381.2011.01524.x","journal-title":"Br J Pharmacol"},{"issue":"27","key":"1168_CR36","doi-asserted-by":"publisher","first-page":"7095","DOI":"10.1523\/JNEUROSCI.3212-15.2016","volume":"36","author":"DJ Titus","year":"2016","unstructured":"Titus DJ, Wilson NM, Freund JE, Carballosa MM, Sikah KE, Furones C, Dietrich WD, Gurney ME, Atkins CM (2016) Chronic cognitive dysfunction after traumatic brain injury is improved with a phosphodiesterase 4B inhibitor. J Neurosci 36(27):7095\u20137108. \n                    https:\/\/doi.org\/10.1523\/JNEUROSCI.3212-15.2016","journal-title":"J Neurosci"}],"container-title":["Molecular Imaging and Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11307-018-1168-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-018-1168-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-018-1168-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,12]],"date-time":"2019-02-12T20:24:27Z","timestamp":1550003067000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11307-018-1168-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,13]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["1168"],"URL":"https:\/\/doi.org\/10.1007\/s11307-018-1168-0","relation":{},"ISSN":["1536-1632","1860-2002"],"issn-type":[{"value":"1536-1632","type":"print"},{"value":"1860-2002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,13]]},"assertion":[{"value":"13 February 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Animal Research Ethics Committee of the Swedish Animal Welfare Agency (Northern Stockholm Region) (N 452\/11) and was performed according to the relevant guidelines of the Karolinska Institutet (\u201cGuidelines for Planning, Conducting and Documenting Experimental Research\u201d (Dnr 4820\/06-600).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This work was sponsored by Takeda Pharmaceutical Company Limited. TU, JGS, GL, and MT were employees of Takeda Pharmaceutical Company Limited when this study was conducted.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}